Bioboosti Device for Insomnia Treatment

Brigham and Women's Hospital21 enrolled

Overview

The purpose of this study is to determine the effects of the Bioboosti device on sleep for patients who have been diagnosed with insomnia.

Insomnia is a common health complaint that is associated with discomfort, loss of productivity, poor health and higher use of healthcare. The use of non-pharmacologic treatments for insomnia has gained much attention in recent years. The investigators are conducting this research because a safe, non-pharmacologic treatment would benefit patients with insomnia, and to see if the Bioboosti device is an effective treatment for insomnia. Subjects will include patients from the clinics who have the diagnosis of insomnia. Study staff will notify the treating physician of a potential subject. If the subject gives permission and would like to obtain more information, study staff will approach them and provide them with the consent form to review. Study staff may also contact them by phone to explain the study and recruit. Subjects will be asked to make 5 visits: Visit 1-- consent form, physical exam, vitals, pregnancy test, sleep log Visit 2-- sleep questionnaires, urine test for hormones associated with sleep, sleep log, placement of EEG Visit 3-- remove EEG, beginning of treatment with Bioboosti device, sleep log Treatment phase-- subjects use the Bioboosti at home for two weeks Visit 4-- return of Bioboosti, sleep questionnaires, urine test for hormones associated with sleep, sleep log, placement of EEG Visit 5-- remove EEG, collect sleep logs

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Insomnia

Interventions

BioboostiDEVICE

Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with insomnia Exclusion Criteria: * Untreated moderate or severe sleep apnea * Major circadian rhythm disorder * Pregnant women * Breastfeeding * Cardiac pacemaker * Cancer * Severe conditions related to heart, brain, kidney and hematopoietic system * Severe/unstable angina pectoris * Arteria coronaria/ peripheral arterial bypass graft * Acute congestive heart failure * Renal insufficiency * Mechanical intestinal obstruction * Any electrical devices

Locations (2)

Brigham and Women's Hospital

Boston, Massachusetts, United States

Brigham and Women's Faulkner Hospital

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Change in Insomnia symptoms before treatment to after treatment

Within subject comparisons before and after treatment, subjects answer questions on their sleep habits.

Time frame: Week 1, Week 4

Change in Sleepiness before treatment to after treatment

Within subject comparisons before and after treatment, subjects answer questions on sleep difficulty.

Time frame: Week 1, Week 4

Secondary Outcomes

Change in EEG from before treatment to after treatment

Ambulatory EEG will be used before treatment and after treatment, using sleep montage per standard AASM criteria and scored by a registered polysomnography technologist using AASM guidelines. Sleep architecture will be reported as the percent of time the subject remains in the different sleep stages. Specifically we will compare percent in REM sleep before and after treatment. The waveform of the EEG that will be assessed during teh study period is delta.

Time frame: Week 2, Week 4

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.